- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
According to our latest study, the global Amyotrophic Lateral Sclerosis (ALS) Treatment market size was valued at USD 308.7 million in 2022 and is forecast to a readjusted size of USD 520.6 million by 2029 with a CAGR of 7.8% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.
North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.
In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.
This report is a detailed and comprehensive analysis for global Amyotrophic Lateral Sclerosis (ALS) Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts, in consumption value ($ Million), 2018-2029
Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Amyotrophic Lateral Sclerosis (ALS) Treatment market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Amyotrophic Lateral Sclerosis (ALS) Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Amyotrophic Lateral Sclerosis (ALS) Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex and Glemark Generics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Amyotrophic Lateral Sclerosis (ALS) Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Riluzole
Edaravone (Radicava)
Other
Market segment by Application
Hospital
Drugs Store
Other
Market segment by players, this report covers
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Amyotrophic Lateral Sclerosis (ALS) Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Amyotrophic Lateral Sclerosis (ALS) Treatment, with revenue, gross margin and global market share of Amyotrophic Lateral Sclerosis (ALS) Treatment from 2018 to 2023.
Chapter 3, the Amyotrophic Lateral Sclerosis (ALS) Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Amyotrophic Lateral Sclerosis (ALS) Treatment market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Amyotrophic Lateral Sclerosis (ALS) Treatment.
Chapter 13, to describe Amyotrophic Lateral Sclerosis (ALS) Treatment research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Amyotrophic Lateral Sclerosis (ALS) Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Amyotrophic Lateral Sclerosis (ALS) Treatment by Type
1.3.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type in 2022
1.3.3 Riluzole
1.3.4 Edaravone (Radicava)
1.3.5 Other
1.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Application
1.4.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Drugs Store
1.4.4 Other
1.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size & Forecast
1.6 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast by Region
1.6.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region, (2018-2029)
1.6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2018-2029)
1.6.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2018-2029)
1.6.6 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Mitsubishi Tanabe Pharma
2.1.1 Mitsubishi Tanabe Pharma Details
2.1.2 Mitsubishi Tanabe Pharma Major Business
2.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Mitsubishi Tanabe Pharma Recent Developments and Future Plans
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Sanofi Recent Developments and Future Plans
2.3 Mylan Pharma
2.3.1 Mylan Pharma Details
2.3.2 Mylan Pharma Major Business
2.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Mylan Pharma Recent Developments and Future Plans
2.4 Apotex
2.4.1 Apotex Details
2.4.2 Apotex Major Business
2.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Apotex Recent Developments and Future Plans
2.5 Glemark Generics
2.5.1 Glemark Generics Details
2.5.2 Glemark Generics Major Business
2.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Glemark Generics Recent Developments and Future Plans
2.6 Covis Pharma
2.6.1 Covis Pharma Details
2.6.2 Covis Pharma Major Business
2.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Covis Pharma Recent Developments and Future Plans
2.7 Sun Pharma
2.7.1 Sun Pharma Details
2.7.2 Sun Pharma Major Business
2.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Sun Pharma Recent Developments and Future Plans
2.8 Lunan Pharma
2.8.1 Lunan Pharma Details
2.8.2 Lunan Pharma Major Business
2.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Lunan Pharma Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Amyotrophic Lateral Sclerosis (ALS) Treatment by Company Revenue
3.2.2 Top 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share in 2022
3.2.3 Top 6 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share in 2022
3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Overall Company Footprint Analysis
3.3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Region Footprint
3.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Type Footprint
3.3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value and Market Share by Type (2018-2023)
4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2018-2023)
5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Application (2024-2029)
6 North America
6.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2018-2029)
6.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2018-2029)
6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
6.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2018-2029)
6.3.2 United States Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
6.3.3 Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
6.3.4 Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2018-2029)
7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2018-2029)
7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
7.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2018-2029)
7.3.2 Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
7.3.3 France Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
7.3.5 Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
7.3.6 Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region
8.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2018-2029)
8.3.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
8.3.3 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
8.3.4 South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
8.3.5 India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
8.3.7 Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
9 South America
9.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2018-2029)
9.2 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2018-2029)
9.3 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
9.3.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2018-2029)
9.3.2 Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
9.3.3 Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
10.3.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2018-2029)
10.3.2 Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
10.3.4 UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
11.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
11.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Chain
12.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Upstream Analysis
12.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Midstream Analysis
12.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Mitsubishi Tanabe Pharma Company Information, Head Office, and Major Competitors
Table 6. Mitsubishi Tanabe Pharma Major Business
Table 7. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 8. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Mitsubishi Tanabe Pharma Recent Developments and Future Plans
Table 10. Sanofi Company Information, Head Office, and Major Competitors
Table 11. Sanofi Major Business
Table 12. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 13. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Sanofi Recent Developments and Future Plans
Table 15. Mylan Pharma Company Information, Head Office, and Major Competitors
Table 16. Mylan Pharma Major Business
Table 17. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 18. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Mylan Pharma Recent Developments and Future Plans
Table 20. Apotex Company Information, Head Office, and Major Competitors
Table 21. Apotex Major Business
Table 22. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 23. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Apotex Recent Developments and Future Plans
Table 25. Glemark Generics Company Information, Head Office, and Major Competitors
Table 26. Glemark Generics Major Business
Table 27. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 28. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Glemark Generics Recent Developments and Future Plans
Table 30. Covis Pharma Company Information, Head Office, and Major Competitors
Table 31. Covis Pharma Major Business
Table 32. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 33. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Covis Pharma Recent Developments and Future Plans
Table 35. Sun Pharma Company Information, Head Office, and Major Competitors
Table 36. Sun Pharma Major Business
Table 37. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 38. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Sun Pharma Recent Developments and Future Plans
Table 40. Lunan Pharma Company Information, Head Office, and Major Competitors
Table 41. Lunan Pharma Major Business
Table 42. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 43. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Lunan Pharma Recent Developments and Future Plans
Table 45. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million) by Players (2018-2023)
Table 46. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Players (2018-2023)
Table 47. Breakdown of Amyotrophic Lateral Sclerosis (ALS) Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 48. Market Position of Players in Amyotrophic Lateral Sclerosis (ALS) Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 49. Head Office of Key Amyotrophic Lateral Sclerosis (ALS) Treatment Players
Table 50. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Type Footprint
Table 51. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Application Footprint
Table 52. Amyotrophic Lateral Sclerosis (ALS) Treatment New Market Entrants and Barriers to Market Entry
Table 53. Amyotrophic Lateral Sclerosis (ALS) Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 54. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (USD Million) by Type (2018-2023)
Table 55. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Share by Type (2018-2023)
Table 56. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Forecast by Type (2024-2029)
Table 57. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2018-2023)
Table 58. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Forecast by Application (2024-2029)
Table 59. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 60. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 61. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 62. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 63. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 64. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 65. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 66. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 67. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 68. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 69. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 70. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 71. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 72. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 73. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 74. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 75. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 76. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 77. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 78. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 79. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 80. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 81. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 82. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 83. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 84. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 85. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 86. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 87. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 88. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 89. Amyotrophic Lateral Sclerosis (ALS) Treatment Raw Material
Table 90. Key Suppliers of Amyotrophic Lateral Sclerosis (ALS) Treatment Raw Materials
List of Figures
Figure 1. Amyotrophic Lateral Sclerosis (ALS) Treatment Picture
Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type in 2022
Figure 4. Riluzole
Figure 5. Edaravone (Radicava)
Figure 6. Other
Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application in 2022
Figure 9. Hospital Picture
Figure 10. Drugs Store Picture
Figure 11. Other Picture
Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Market Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 16. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Region in 2022
Figure 17. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 18. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 19. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 20. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 21. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 22. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Players in 2022
Figure 23. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 24. Global Top 3 Players Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share in 2022
Figure 25. Global Top 6 Players Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share in 2022
Figure 26. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Share by Type (2018-2023)
Figure 27. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Forecast by Type (2024-2029)
Figure 28. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Share by Application (2018-2023)
Figure 29. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Forecast by Application (2024-2029)
Figure 30. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 31. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 32. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 33. United States Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 34. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 35. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 36. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 37. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 38. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 39. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 40. France Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 41. United Kingdom Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 42. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 43. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 44. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 45. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 46. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 47. China Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 48. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 49. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 50. India Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 51. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 52. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 53. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 54. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 55. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 56. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 57. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 58. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 59. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 60. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 61. Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 62. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 63. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 64. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
Figure 65. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
Figure 66. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Manufacturing Cost Structure Analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment in 2022
Figure 69. Manufacturing Process Analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment
Figure 70. Amyotrophic Lateral Sclerosis (ALS) Treatment Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
